XML 46 R31.htm IDEA: XBRL DOCUMENT v3.21.1
LONG-TERM DEBT (Tables)
 9 Months Ended
May 01, 2021
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s long-term debt consisted of the following:
(in thousands)
Average Interest Rate at
May 1, 2021
Fiscal Maturity YearMay 1,
2021		August 1,
2020
Term Loan Facility3.61%2026$1,002,253 $1,773,000 
ABL Credit Facility1.50%2024839,290 756,712 
Senior Notes6.75%2029500,000 — 
Other secured loans5.17%2024-202539,751 49,268 
Debt issuance costs, net(36,374)(45,846)
Original issue discount on debt(17,523)(35,508)
Long-term debt, including current portion2,327,397 2,497,626 
Less: current portion of long-term debt(13,182)(70,632)
Long-term debt$2,314,215 $2,426,994 
Schedule of Line of Credit Facilities
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
May 1,
2021		August 1,
2020
Certain inventory assets included in Inventories, net and Current assets of discontinued operations$2,352,755 $2,270,892 
Certain receivables included in Accounts receivable, net and Current assets of discontinued operations$1,064,392 $1,077,682 
(1)The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Intangibles, net in the Condensed Consolidated Balance Sheets as of May 1, 2021 and August 1, 2020.
Unused credit and fees under the ABL Credit Facility (in thousands, except percentages):May 1, 2021
Outstanding letters of credit
$117,501 
Letter of credit fees
1.375 %
Unused credit
$1,142,800 
Unused facility fees
0.25 %